TreeFrog Therapeutics’ Post

From Breaking Bad to Biotechnology: Exploring the New Frontier Join us as we dive into the fascinating world of biotechnology, from the iconic TV series Breaking Bad to the latest advancements in cell therapy. Discover how purified antibodies are revolutionizing medicine and how this cutting-edge field combines both passion and practicality. #BreakingBad #Biotechnology #CellTherapy #MedicalAdvancements #PurifiedAntibodies #ScienceAndTechnology #BiotechRevolution #MedicalInnovation #CellularResearch #HealthcareAdvances

From Breaking Bad to Biotechnology: Exploring the New Frontier Join us as we dive into the fascinating world of biotechnology, from the iconic TV series Breaking Bad to the latest advancements in cell therapy. Discover how purified antibodies are revolutionizing medicine and how this cutting-edge field combines both passion and practicality. #BreakingBad #Biotechnology #CellTherapy #MedicalAdvancements #PurifiedAntibodies #ScienceAndTechnology #BiotechRevolution #MedicalInnovation #CellularResearch #HealthcareAdvances

🔬✨ In this week's #TechTales post, we delve into our #nanoshuttle technology🚀 MOF nanoparticles are created by repeating a unit cell, forming a network with symmetrically repeated porosity. This intricate structure allows for exceptional adsorption properties, which is key to improved cargo uptake. At Vector Bioscience Cambridge, we leverage the porosity of MOFs to encapsulate small- and macro-molecules, enabling more effective and targeted drug delivery. This innovative approach supports the development of novel cancer treatments, enhancing patient outcomes. Stay tuned for our next #TechTales posts as we continue to explore the science driving our breakthroughs🧬💊🔬 #DrugDelivery #Nanotechnology #Biopharma #Innovation #MOFs #Science #Biotech #CancerTreatment #ResearchAndDevelopment

🤝 Finally at the #DeutscheBiotechnologietage and waiting to speak with you! Let's exchange ideas! Aparna Sekar and Dr. Regina Ohmer are ready to discuss the application of multi-omics single cell sequencing, driving the potential of biotechnology in health research 👩⚕️ #singlecell #multiomics #precisionmedicine

Recent advances in #artificialintelligence and #machinelearning are transforming just about every area of business. But humanity will arguably benefit most from the plethora of AI-fueled advances in life sciences and biotechnology. Read how three of our Vision Funds' #biotech portfolio companies are harnessing these technologies to target intractable cancers, inflammatory and neurologic diseases, and why their CEOs are so optimistic about the days ahead: https://lnkd.in/gzpMiqjb

Proteios has been selected as a member of CASA-Bio (Catalyzing Across Sectors to Advance the Bioeconomy) to advance biotechnology and biomanufacturing through foundational and use-inspired research and development.  CASA-Bio was created on September 2022 by Executive Order (EO) on “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.”  Proteios is participating under the “Human Health” EO Bioeconomy theme with our novel multidimensional cell isolation technology to provide clinicians with unprecedented access to immune cell subpopulations and precise control of cell therapy compositions.  Cell therapies, especially in cancer treatment like CAR-T cell therapies, present a vast untapped potential but face significant challenges in basic science, cell sourcing, manufacturing, and in vivo performance control.  Proteios looks forward to addressing these challenges to improve the range of conditions for which cell therapies can be routinely applied.

Non-dilutive #governmentfunding webinar is TODAY, Jan 18 @ 12pm ET. Hear from experts on #government #grants for #health innovators #lifesciences #biotech #therapeutics #medicaldevices #diagnostics #digitalhealth and more! See link below.

Oligonucleotide therapies are a rapidly advancing field of biotechnology that promise to cure previously undruggable diseases with small fragments of RNA. Leveraging advances in accessible computation to power ultra high-throughput experimentation, Elsie Biotechnologies is building a new platform for the design, testing, and validation of oligonucleotide therapeutics at an unprecedented scale. Learn about the mechanics of their platform and how their partnership with LatchBio has accelerated their science. Read out the full case study here: https://lnkd.in/g8eFuSti Have questions about Elsie or their science? Register for our webinar to ask Elsie's co-founder, Dillon Flood, directly. https://lnkd.in/gewrzxTG

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is glad to see the mounting interest in Nonalcoholic Steatohepatitis (NASH). The field was notably understudied until recently, when Genflow Biosciences and fellow pioneers began developing promising new treatments revolving around #SIRT6. Our CEO, Dr Eric Leire, points to a recent EMBO Press report as an example of the growing attention, which also lends support to our research in #NASH. Read the report here: https://loom.ly/Z_O_-tE #livertreatment #biotech #genetherapy